巨细胞病毒是儿童听力损失的危险因素:系统综述
有症状CMV感染新生儿出生时听力损失患病率超过33%,无症状者低于15%;儿童期有症状者超40%,无症状者低于30%。迟发性和进行性听力损失是先天性CMV感染的特征,建议将CMV纳入筛查和监测风险因素。
要点
- 有症状先天性CMV感染新生儿出生时听力损失患病率超过33%。
- 无症状先天性CMV感染儿童期听力损失患病率低于30%。
- 迟发性和进行性听力损失是先天性CMV感染的特征。
核心结论
- 有症状和无症状先天性CMV感染均应视为出生时及儿童期听力损失和进行性听力损失的危险因素。
- CMV应纳入听力筛查和监测项目的风险因素,并在听力损失儿童临床随访中加以考虑。
研究设计与样本
- 系统综述检索MEDLINE、Ovid MEDLINE(R) Daily和Ovid MEDLINE(R)、Embase及CINAHL数据库。
- 主要结局为先天性或儿童期(出生至18岁)起病的永久性双侧或单侧听力损失,次要结局为进行性听力损失。
- 采用McMaster大学定量研究质量评估工具评价个体研究质量,使用GRADE对证据质量和强度分级,完成叙述性综合。
主要发现
- 有症状CMV感染新生儿出生时听力损失患病率超过33%,无症状感染者低于15%。
- 儿童期有症状CMV感染者听力损失患病率超过40%,无症状者低于30%。
- 迟发性和进行性听力损失似乎是先天性CMV感染的特征。
- 各研究报告了所有程度及双侧和单侧听力损失,无论出生时有症状与否,无法得出听力损失特征的结论。
- 听力损失模式包括稳定、进行性和波动性,并有听力改善(有时至正常听力)的记录,见于有症状/无症状先天性CMV感染儿童、先天/早发/迟发性听力损失及接受/未接受抗病毒治疗的儿童。
关键数值与推荐
- 有症状CMV感染新生儿出生时听力损失患病率超过33%。
- 无症状CMV感染新生儿出生时听力损失患病率低于15%。
- 有症状CMV感染儿童期听力损失患病率超过40%。
- 无症状CMV感染儿童期听力损失患病率低于30%。
临床怎么用
- 应将CMV作为听力筛查和监测项目的风险因素。
- 在听力损失儿童的临床随访中应考虑先天性CMV感染。
- 对有症状和无症状先天性CMV感染儿童均需关注迟发性和进行性听力损失。
局限性
- 各研究对听力损失的定义、损失程度及侧别报告不一致。
- 无法就听力损失的特征得出结论。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Permanent hearing loss is an important public health issue in children with consequences for language, social, and academic functioning. Early hearing detection, intervention, and monitoring are important in mitigating the impact of permanent childhood hearing loss. Congenital cytomegalovirus (CMV) infection is a leading cause of hearing loss. The purpose of this review was to synthesize the evidence on the association between CMV infection and permanent childhood hearing loss. DESIGN: We performed a systematic review and examined scientific literature from the following databases: MEDLINE, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R), Embase, and CINAHL. The primary outcome was permanent bilateral or unilateral hearing loss with congenital onset or onset during childhood (birth to 18 years). The secondary outcome was progressive hearing loss. We included studies reporting data on CMV infection. Randomized controlled trials, quasi-experimental studies, nonrandomized comparative and noncomparative studies, and case series were considered. Data were extracted and the quality of individual studies was assessed with the Qualitative Assessment Tool for Quantitative Studies (McMaster University). The quality and strength of the evidence were graded using the Grading of Recommendations Assessment, Development and Evaluation (GRADE). A narrative synthesis was completed. RESULTS: Sixty-five articles were included in the review. Prevalence of hearing loss at birth was over 33% among symptomatic CMV-infected newborns and less than 15% in asymptomatic infections. This difference in prevalence was maintained during childhood with more than 40% prevalence reported for symptomatic and less than 30% for asymptomatic CMV. Late-onset and progressive hearing loss appear to be characteristic of congenital CMV infections. Definitions of hearing loss, degree of loss, and reporting of laterality varied across studies. All degrees and both bilateral and unilateral loss were reported, regardless of symptomatic and asymptomatic status at birth, and no conclusions about the characteristics of hearing loss could be drawn. Various patterns of hearing loss were reported including stable, progressive, and fluctuating, and improvement in hearing (sometimes to normal hearing) was documented. These changes were reported in children with symptomatic/asymptomatic congenital CMV infection, presenting with congenital/early onset/late-onset hearing loss and in children treated and untreated with antiviral medication. CONCLUSIONS: Symptomatic and asymptomatic congenital CMV infection should be considered a risk factor for hearing loss at birth and during childhood and for progressive hearing loss. Therefore, CMV should be included as a risk factor in screening and surveillance programs and be taken into account in clinical follow-up of children with hearing loss.
引用
- Vos B, Noll D, Whittingham J, et al. Cytomegalovirus-A Risk Factor for Childhood Hearing Loss: A Systematic Review. Ear Hear. 2021. PMID: 33928914. doi:10.1097/AUD.0000000000001055
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。